Director/PDMR Shareholding

RNS Number : 6414Z

Hikma Pharmaceuticals Plc

19 March 2012

 



Hikma Pharmaceuticals PLC - Share Transactions

LONDON, 19 March 2012: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have exercised awards which vested on 19 March 2012 under the 2005 Long Term Incentive Plan ("LTIP") and which the holders were required to exercise as part of the vesting process. The exercise price under the LTIP is £nil. The persons concerned elected to retain all the shares exercised.

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.

PDMR	Type of Transaction	Exercised	Date		Price	Shares Disposed	Remaining Holding
Said Darwazah	Exercise of LTIP 2009	115,000 (0.06% ISC)	19 March 2012		£7.27	Nil	418,445 (0.21%)
Mazen Darwazah	Exercise of LTIP 2009	69,000 (0.04% ISC)	19 March 2012		£7.27	Nil	868,225 (0.44%)
Khalid Nabilsi	Exercise of LTIP 2009	46,000 (0.02% ISC)	19 March 2012		£7.27	Nil	196,784 (0.10%)
Riad Mishlawi	Exercise of LTIP 2009	27,600 (0.01% ISC)	19 March 2012		£7.27	Nil	42,600 (0.02%)

- ENDS -

Enquiries                                                                                                                                      

Henry Knowles                                                                                [phone]

Company Secretary, Hikma Pharmaceuticals PLC

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

 

END

 

 

RDSBLGDXCSBBGDC